Indian Pharma Sector: Evolving to Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Indian Pharma Sector: Evolving to Innovation


Pharmaceutical Technology


Destiny to new drug discovery

The growing realization of limited products available for market as a result of product patent law has compelled futuristic Indian pharmaceutical companies to a paradigm shift from reverse engineering to new drug discovery. The government of India also has encouraged innovation by providing fiscal incentives to R&D companies. In the recently presented budget, the benefit of 150% weighted deduction on R&D expenditure was extended up to 2015. Additionally, according to recommendations made by the Committee for Pharmaceutical Research and Development's Dr. R.A. Mashelkar, weighted deduction of 200% will be given to any company, if they meet the following specified norms: a) Investment of 3% of annual sales or Rs.500 million (approx $1.2 million US) per annum (average of last 3 years), or whichever is higher, is spent on research; b) 200 scientists employed at least for the period of one year; d) filed 10 patents resulting from research conducted in India; and d) the manufacturing facility is approved by two reputed regulatory agencies. Furthermore, the Department of Science and Technology has devised a number of schemes to encourage discovery research in the country. However, domestic companies are yet to invest in new drug discovery because of financial limitations and risk of failure.

The research environment will definitely take positive course in due time, as urgency to innovate to remain an active player has been mandated by Indian pharma, and as dedicated facilities exclusively for new drug discovery have been created. There is already a trend of "reverse brain drain" conducive to a research environment and IPR protection and fiscal benefits offered by India's government to facilitate the discovery of new drugs within the country. There is still a need to evolve novel biology and chemistry, as almost all of discovery research is analogizing or patent bursting.

The future of new drug discovery in India is destined to witness a favorable shift in due course, with MNCs opting for alliances and joint ventures with innovative Indian firms taking advantage of scientific talents, cost and time efficiency, government policies, and a heterogeneous patient pool. Indian companies, which offer comprehensive integrated infrastructure from discovery to development, will be most favored.

Dr. Aftab lakdawala is an expert on setting up laboratories geared toward new drug discovery. He was responsible for setting up Glenmark and Wockhardt's facilities and now works with Avaant Pharmaceuticals.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here